Absci (NASDAQ:ABSI) Earns Buy Rating from Needham & Company LLC

Absci (NASDAQ:ABSI)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock. Needham & Company LLC’s target price indicates a potential upside of 143.06% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley cut Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 target price on the stock. in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a research note on Wednesday, January 21st. Finally, HC Wainwright lifted their price target on Absci from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.08.

Absci Stock Down 1.4%

Shares of ABSI opened at $2.88 on Wednesday. The firm has a market capitalization of $440.70 million, a PE ratio of -3.39 and a beta of 2.12. The firm has a 50-day moving average price of $2.77 and a 200 day moving average price of $3.21. Absci has a 52-week low of $2.01 and a 52-week high of $5.23.

Absci (NASDAQ:ABSI) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $1.38 million. Absci had a negative return on equity of 62.33% and a negative net margin of 4,113.68%. On average, equities analysts expect that Absci will post -0.89 EPS for the current year.

Insider Activity at Absci

In other Absci news, insider Andreas Busch bought 100,000 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was acquired at an average cost of $2.29 per share, with a total value of $229,000.00. Following the completion of the purchase, the insider directly owned 421,446 shares in the company, valued at approximately $965,111.34. This trade represents a 31.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Sean Mcclain sold 26,761 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $2.99, for a total transaction of $80,015.39. Following the sale, the chief executive officer owned 8,334,567 shares of the company’s stock, valued at $24,920,355.33. The trade was a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 10.49% of the company’s stock.

Institutional Investors Weigh In On Absci

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP acquired a new position in shares of Absci in the 3rd quarter worth $26,000. Scientech Research LLC purchased a new stake in shares of Absci during the third quarter valued at $31,000. HB Wealth Management LLC acquired a new position in shares of Absci in the 3rd quarter valued at $31,000. Principal Financial Group Inc. acquired a new position in shares of Absci in the 3rd quarter valued at $31,000. Finally, Xponance LLC purchased a new position in Absci in the 4th quarter worth about $37,000. Institutional investors and hedge funds own 52.05% of the company’s stock.

Key Absci News

Here are the key news stories impacting Absci this week:

• Positive Sentiment: HC Wainwright published a long‑range bullish view (FY2030) forecasting EPS of $0.61 and reiterating a “Buy” stance with an $8.00 price objective — a signal of strong upside expectations from a sell‑side shop that can support buying interest.
• Positive Sentiment: Needham & Company reaffirmed its Buy rating and $7.00 price target, reiterating institutional support and another catalyst for upside if the company executes on its pipeline programs. Needham Reaffirmed Buy
• Neutral Sentiment: Management’s Q4 2025 earnings call/transcripts emphasize strategic progress and pipeline advancement (discussion of moves toward ABS‑201 and broader platform work), which underpins long‑term narrative even as near‑term results are mixed. ABSI Q4 2025 Earnings Call Transcript (Yahoo)
• Neutral Sentiment: Full call transcripts are available for investors who want the verbatim management commentary and Q&A to judge execution risk and timelines. ABSI Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Coverage highlights Absci’s cash‑burn profile and runway concerns — analysts and commentaries are watching how quickly R&D spend and program timing will pressure liquidity, which increases downside risk if financing terms or dilution become necessary. Here’s Why We’re Watching Absci’s Cash Burn Situation
• Negative Sentiment: Analyst repositioning: Seeking Alpha reported a downgrade to “Hold” citing that ABS‑101 has been deprioritized while management pivots resources to ABS‑201 — the program shift raises execution and timeline uncertainty, pressuring sentiment. Absci: Downgrade To ‘Hold’
• Negative Sentiment: Recent coverage and pre‑market notes flagged shares moving lower after the quarter; the sell‑side reaction reflects the mix of a revenue/EPS miss in the recent quarter and ongoing execution/cash concerns described above. Pre‑Market Movers: Absci

About Absci

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.